USFDA nod to drug firm Alembic Pharma for insomnia treatment drug
The approved abbreviated new drug application (ANDA) is the therapeutic equivalent to the reference listed drug product (RLD) Restoril Capsules.
- Country:
- India
Drug firm Alembic Pharmaceuticals has received approval from the US health regulator for Temazepam capsules, used for treatment of insomnia.
The company has got approval from the US Food and Drug Administration (USFDA) to market the drug in the strength of 7.5mg, 15mg, 22.5mg and 40mg, Alembic Pharmaceuticals said in a BSE filing.
The approved abbreviated new drug application (ANDA) is the therapeutic equivalent to the reference listed drug product (RLD) Restoril Capsules.
Quoting IQVIA sales data, the company said, Temazepam capsules 7.5mg, 15mg, 22.5mg and 40mg had an estimated market size of USD 48 million for 12 months, ending December 2017.
The company's stock was trading at Rs 567 apiece, up 1.33 per cent, on the BSE.
(With inputs from agencies.)
- READ MORE ON:
- Insomnia
- Therapy
- Oral administration
- Drug Enforcement Administration
- Capsule
- US Foods
- Pharmaceutical industry
- Food and Drug Administration
- United States presidential approval rating
- Drug firm Alembic Pharmaceuticals
- Restoril Capsules
- insomnia treatment drug
- Drug Administration
- Temazepam capsules
- US Food
- US health regulator
- USFDA nod
- approval
- estimated market size of USD
- Business News
ALSO READ
Seymour welcomes approval of cold and flu medicines containing pseudoephedrine
Majority of Goa residents express disapproval of BJP, says AAP MLA Venzy Viegas
US airlines urge Biden administration to halt approval of extra flights between US and China
Environmentalists decry Biden administration's approval of massive oil export terminal along Texas coast
Paytm accelerates user migration to PSP Banks with NPCI approval: Axis Bank, HDFC, SBI, YES Bank operational on TPAP